Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Anuj Shah, Ruchit Shah, Nehemiah Kebede, Ateesha F. Mohamed, Marc Botteman, Reg Waldeck, Arif Hussain

Journal of Medical Economics · 2019 · 31 citations · 27 references

DOIFull text

Open access

Concepts

Abstract

AEs increase the economic burden and therapy discontinuation among nmPC patients receiving secondary hormonal therapies subsequent to ADTs. These patients should be carefully evaluated for AEs to reduce therapy discontinuation, HCRU, and direct medical costs.

References

27